Valeant Pharmaceuticals International Inc (VRX.N)

VRX.N on New York Stock Exchange

140.00USD
17 Dec 2014
Price Change (% chg)

$3.08 (+2.25%)
Prev Close
$136.92
Open
$135.78
Day's High
$140.12
Day's Low
$135.78
Volume
253,172
Avg. Vol
372,536
52-wk High
$152.92
52-wk Low
$106.03

VRX.N

Chart for VRX.N

About

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded... (more)

Overall

Beta: 0.90
Market Cap (Mil.): $45,843.62
Shares Outstanding (Mil.): 335.67
Dividend: --
Yield (%): --

Financials

  VRX.N Industry Sector
P/E (TTM): 92.64 37.01 37.62
EPS (TTM): 1.48 -- --
ROI: 2.05 18.05 17.39
ROE: 9.98 18.84 18.30
Search Stocks

Exclusive: Valeant to drop deal-making in near term to cut debt, boost stock

NEW YORK/WINNIPEG - Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters.

09 Dec 2014

UPDATE 1-Market Chatter-Corporate finance press digest

Dec 9 - The following corporate finance-related stories were reported by media:

09 Dec 2014

A

21 Nov 2014

CORRECTED-BRIEF-Valeant Pharma reports 0.1 percent stake in Allergan

(Corrects first bullet point to remove incorrect reference to Valeant's prior stake in Allergan)

21 Nov 2014

Valeant slashes stake in Allergan after losing bid

- (Refiles Nov. 20 story to correct reference to previous stake)

21 Nov 2014

CORRECTED-Valeant slashes stake in Allergan after losing bid

Nov 20 - Valeant Pharmaceuticals International Inc said it cut its stake in Allergan Inc to 0.1 percent, three days after Actavis Plc trumped its offer for the Botox maker.

21 Nov 2014

Valeant Pharma says may buy back up to $2 billion worth of securities

- Canada's Valeant Pharmaceuticals International Inc said it may buy back up to $2 billion worth of securities, replacing a previous $1.5 billion program under which it bought back no securities.

20 Nov 2014

Valeant Pharma says may buy back up to $2 bln worth of securities

- Canada's Valeant Pharmaceuticals International Inc said it may buy back up to $2 billion worth of securities, replacing a previous $1.5 billion program under which it bought back no securities.

20 Nov 2014

UPDATE 1-Valeant Pharma says may buy back up to $2 bln worth of securities

Nov 20 - Canada's Valeant Pharmaceuticals International Inc said it may buy back up to $2 billion worth of securities, replacing a previous $1.5 billion program under which it bought back no securities.

20 Nov 2014

Valeant Pharma may buy back up to $2 bln worth of securities

Nov 20 - Canada's Valeant Pharmaceuticals International Inc said it may buy back up to $2 billion in senior notes, shares and other securities.

20 Nov 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00
Provider: Directors Deals Ltd.
$12.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks